Can Alcoholics Get a Liver Transplant?

People with alcohol-related liver disease can and do receive liver transplants, and alcohol-related liver disease is now one of the leading reasons for transplantation in the United States. The path to getting listed is more complicated than for most other liver conditions, though. Most transplant centers have historically required at least six months of sobriety before placing a patient on the waiting list, but that rule is increasingly being bypassed for patients who are critically ill and unlikely to survive without a new liver. What actually determines eligibility is a combination of medical severity, a psychosocial evaluation, and a transplant team’s judgment about a person’s likelihood of staying sober afterward.

The Six-Month Rule and Why It Is Losing Ground

For decades, the standard at most transplant centers has been that patients with alcohol-related liver disease must demonstrate at least six months of abstinence before they can be placed on a transplant waiting list. The logic sounds reasonable: give the liver time to recover on its own, prove commitment to sobriety, and reduce the chance of relapse after transplant. In practice, this threshold was never based on strong evidence. It was adopted in the early 1990s as a consensus guideline, not because studies showed it improved outcomes. Reviews of the data have consistently found that the six-month cutoff has never been shown to reliably predict post-transplant survival or sobriety.¹

The problem with a rigid sobriety clock is that some patients are too sick to wait. People with severe alcoholic hepatitis who do not respond to steroid treatment face extremely high short-term mortality. Telling someone with a three-month life expectancy to come back in six months is, in effect, a death sentence. That tension has pushed many transplant programs to adopt more flexible policies, evaluating candidates case by case rather than enforcing a blanket timeline.²

Early Transplant for Severe Alcoholic Hepatitis

The pivotal study that cracked open the debate was a 2011 French-Belgian trial. Researchers took patients with severe alcoholic hepatitis who had failed medical therapy and transplanted a carefully selected group of them without requiring six months of sobriety. The results were stark: the six-month survival rate was about 77% in the transplanted group compared with 23% in matched controls who did not receive a transplant. That survival advantage held for at least two years.³ Only three of the 26 transplanted patients returned to drinking, and those relapses happened well over a year after surgery.⁴

Follow-up studies from the United States confirmed the pattern. One large study found that patients transplanted early for severe alcoholic hepatitis had one-year and three-year survival rates of 94% and 84%, with sustained heavy drinking afterward in roughly one in six patients at three years.⁴ A later European controlled study added nuance, though. It found that while early transplant clearly saved lives compared with no transplant, the rate of returning to heavy drinking was higher in the early-transplant group than in patients who went through the standard pathway with a full six months of sobriety first.⁵ Post-transplant survival was similar between the two groups, but the early-transplant patients spent more time drinking heavily afterward. That tradeoff is central to ongoing debate: early transplant unquestionably saves lives in the short term, but it requires more intensive follow-up to manage relapse.

How Transplant Teams Decide Who Gets Listed

Sobriety duration is only one piece of the evaluation. Every transplant candidate goes through a psychosocial assessment, usually conducted by addiction psychiatrists, psychologists, and social workers. These evaluations try to gauge whether the person has a realistic support system, insight into their drinking, willingness to engage in treatment, and manageable psychiatric conditions. Several standardized scoring tools exist for this purpose, and research shows that some of these tools can meaningfully distinguish between patients who are likely to succeed and those at higher risk of relapse.⁶

What actually predicts relapse after transplant? The research points to a few consistent risk factors: shorter pre-transplant sobriety, starting to drink at a young age, existing psychiatric conditions like depression or anxiety, lack of a strong social support network, and a history of continuing to drink even after medical advice to stop.⁷ One study found that comorbid psychiatric illness increased the odds of post-transplant relapse roughly fivefold, and continued drinking after being told to stop by a doctor tripled the odds.⁸ Pre-transplant sobriety of less than six months predicted relapse with about 84% accuracy in another analysis.⁹ These findings help explain why transplant teams weigh the whole picture rather than relying on any single criterion.

How Survival Compares to Other Transplant Recipients

One of the strongest arguments for transplanting patients with alcohol-related liver disease is that their outcomes are essentially on par with patients transplanted for other causes. A large U.S. analysis found that one-year patient survival was about 91% for alcohol-related disease compared with 90% for all other causes. At five years the numbers converged around 79-80%. A modest gap opened at ten years, with alcohol-related disease patients at about 63% survival versus 68% for others.¹⁰ A Scandinavian study actually found a trend in the opposite direction, with alcohol-related disease patients showing 75% ten-year patient survival compared with 65% in controls, though that difference was not statistically significant.¹¹

The takeaway is that alcohol-related liver disease is not a lesser indication for transplant in terms of outcomes. Patients do well, and the new liver functions reliably. The slightly lower long-term numbers in some studies appear to be driven not by liver failure but by other complications, especially cancer and heart disease, which are discussed below.

What Happens When Someone Drinks Again After Transplant

Relapse happens. Across studies, roughly a quarter to a third of transplant recipients with alcohol-related disease return to some level of drinking. But not all relapse is equal. An occasional slip does not appear to reduce survival. The danger comes from returning to heavy, sustained drinking. One study found that among patients who relapsed, most drank heavily, and about one in six of those heavy drinkers developed graft dysfunction.¹²

The long-term picture clarifies the stakes. One analysis found no survival difference at one or five years between those who stayed sober and those who relapsed, but at ten years, patients drinking heavily had dramatically lower survival, around 45% compared with 86% for those who stayed abstinent. The increased mortality was not primarily from liver failure or graft rejection but from new cancers and cardiovascular events.¹³ This is why transplant teams focus so heavily on relapse prevention: it is the long game that matters most.

Monitoring Sobriety With Blood Tests

Traditionally, transplant teams relied on self-reporting and urine tests to track whether patients were drinking. Both methods have significant blind spots. A blood marker called phosphatidylethanol, or PEth, has changed the landscape. PEth is a substance formed in cell membranes only when alcohol is present, and it stays detectable for several weeks after drinking, making it much harder to hide a slip. Research in transplant recipients has shown that PEth catches cases of moderate-to-heavy drinking that patients do not disclose to their transplant teams.¹⁴

PEth monitoring is now widely used for transplant candidates with alcohol-related disease, but a recent study found concerning numbers: more than half of patients transplanted for alcohol-related disease tested positive for PEth at some point during follow-up, with about a third showing levels suggestive of heavy drinking.¹⁵ The same study noted that very few patients transplanted for other conditions were being monitored with PEth at all, even though some of them had unrecognized alcohol-related components to their liver disease. PEth is also proving valuable before transplant, during the candidacy period, to verify abstinence claims with objective data.¹⁶

Cancer and Heart Disease After Transplant

The immunosuppressive drugs required after transplant raise everyone’s cancer risk, but people transplanted for alcohol-related disease face a higher burden than most. The risk of cancers in the mouth, throat, and lungs is particularly elevated in this group.¹⁷ The incidence of new tumors after transplant ranges from roughly 3% to 16% in patients with alcoholic cirrhosis, and these cancers appear significantly more often than in patients transplanted for other reasons. Skin and urinary tract tumors are also more common.¹⁸ In some studies, cancer is the leading cause of death in this population, with smoking after transplant identified as a major independent risk factor.¹⁹

Cardiovascular disease tells a similar story. Patients transplanted for alcohol-related cirrhosis have a higher rate of major cardiac events afterward, roughly 8% compared with about 5% for other indications.²⁰ A national U.S. sample confirmed that alcoholic cirrhosis independently predicted major adverse cardiovascular events within 30 and 90 days of transplant.²¹ Both the cancer and cardiovascular risks appear closely linked to ongoing tobacco use, which is extremely common in this population. Quitting smoking after transplant is arguably as important as staying sober for long-term survival.²²

Integrated Addiction Care Makes a Measurable Difference

One of the clearest findings in recent years is that embedding addiction specialists directly into transplant programs improves outcomes. A French study found that patients who received structured addiction follow-up after transplant had significantly lower rates of severe alcohol relapse. That same follow-up was also associated with fewer cardiovascular events, suggesting the benefits extend beyond sobriety alone.²³

In the U.S., early data from multidisciplinary clinics that combine hepatology, addiction medicine, and behavioral health show promising results. One such clinic reported significant drops in liver enzyme levels, disease severity scores, and the proportion of patients with active severe alcohol use disorder between their first and follow-up visits.²⁴ The pharmacotherapy side is limited, though. For patients who still have significant liver damage, most medications used to treat alcohol use disorder are either unsafe or untested. Baclofen is the only drug that has been tested in randomized trials in people with advanced liver disease, and it has shown both effectiveness in reducing drinking and a safe profile in that population.²⁵

When the Liver Recovers Without a Transplant

Not every person with advanced alcohol-related liver disease needs a transplant. Sustained abstinence can produce remarkable recovery. A recent study found that roughly a third of patients with decompensated alcohol-related cirrhosis, meaning their liver had already failed enough to cause major complications, achieved what researchers call “re-compensation” through consistent abstinence: full resolution of liver-related complications along with recovery of liver function within about five years.²⁶

Among patients with severe alcoholic hepatitis who were denied early transplant or did not qualify, about a quarter experienced spontaneous recovery. Younger age, lower disease severity scores, and lower clotting abnormality at the time of evaluation were associated with recovering without a transplant. However, only a small fraction of those who recovered reached a truly stable, compensated state.²⁷ This is encouraging but not a reason to delay transplant evaluation in someone who is critically ill. The sickest patients cannot wait to see whether their liver bounces back.

Gender Gaps in Getting Listed

Access to transplant is not equal. Studies consistently show that women with alcohol-related liver disease are less likely to be listed for transplant and less likely to ultimately receive one. One analysis found that women had about 36% lower odds of being listed compared with men. Even after adjusting for disease severity, women were more than twice as likely to be removed from the waitlist and about half as likely to receive a transplant.²⁸

The gap appears to be driven partly by higher rates of psychiatric conditions and lower employment among women in these studies, both of which can negatively influence psychosocial assessments. But researchers suspect gender-specific stigma also plays a role. Women face harsher social judgment for heavy drinking, which may affect how transplant teams perceive them, even unconsciously. A separate study confirmed the pattern: men with alcohol-related liver disease were roughly twice as likely to be listed and transplanted compared with women, despite women having fewer lifetime substance use consequences on average.²⁹ Addressing this disparity likely requires both better psychiatric support for women candidates and awareness among transplant teams of potential bias.

Living Donor Transplants and the Stigma Question

Most liver transplants in the United States come from deceased donors, which creates an inherent scarcity problem and feeds the ethical debate over whether someone who “caused” their own disease should receive an organ that could go to someone else. Living donor liver transplant, where a healthy person donates part of their liver, sidesteps that concern. The donated lobe regrows in both the donor and recipient, so no deceased-donor organ is consumed. Data from a large U.S. study of living-donor transplants found no significant difference in quality-of-life outcomes for donors who gave to patients with alcohol-related disease versus those who donated for other reasons.³⁰

The ethical tension is real but often overstated. Many conditions that lead to liver failure involve behavioral components: obesity-related fatty liver disease, hepatitis C acquired through intravenous drug use, liver cancer linked to chronic hepatitis B that went untreated. Singling out alcohol-related disease as uniquely “self-inflicted” does not hold up under scrutiny, especially as the medical community increasingly treats alcohol use disorder as a chronic brain disease rather than a moral failing.

A Younger Population Driving the Numbers Up

The demographics of alcohol-related liver transplantation have shifted dramatically. The number of people added to the waitlist for alcohol-related liver disease has roughly doubled over recent years, and the fastest-growing groups are young and middle-aged adults.³¹ By 2023, about 16% of all alcohol-related waitlist additions were adults aged 18 to 39, a group that was barely represented a decade earlier.³² The rise has been attributed to increasing rates of heavy drinking across younger cohorts, a trend accelerated by the COVID-19 pandemic. For transplant programs, this means grappling with candidates who have decades of potential life ahead of them but who developed severe liver disease in a compressed timeline, often without the long drinking history that older patients typically show. The psychosocial evaluation takes on added weight in these cases, because the risk factors for relapse, particularly young age at first drink and limited sobriety track record, are almost definitionally present.